News

Applied Therapeutics Shares Third Quarter Results and Updates

Applied Therapeutics Shares Third Quarter Results and Updates

Applied Therapeutics' Financial Performance Update

NEW YORK, Nov. 13, 2025 -- Applied Therapeutics, Inc. (NASDAQ: APLT), a clinical-stage biopharmaceutical company, announced its financial results for the third quarter that concluded on September 30, 2025. In this period, the company made significant progress in its clinical programs, especially for govorestat, a drug under development for treating serious rare diseases.

Regulatory Strategy and FDA Engagement

Update on CMT-SORD Meetings

Applied Therapeutics has been engaged in fruitful dialogue with the FDA regarding the development of govorestat aimed at treating Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD). Following a productive Type C meeting with the FDA, the company is dedicated to refining its regulatory strategy as it plans to submit a request for an additional meeting to discuss a potential Phase 3 trial.

Classic Galactosemia Discussions

The company has also scheduled a crucial meeting with the FDA to discuss the regulatory pathway for govorestat concerning the treatment of Classic Galactosemia. This discussion comes in the wake of a Complete Response Letter received previously and aims to align both parties on the necessary steps moving forward.

Development News on Govorestat

Recent Clinical Findings

New data released regarding govorestat highlights a significant achievement in treating PMM2-CDG, a severe genetic condition with high unmet medical need. Findings from a single-patient investigator-initiated study were presented at the 2025 ASHG Annual Meeting, showcasing a substantial reduction in sorbitol levels and improving clinical outcomes without adverse effects.

Commitment to Patients with Rare Diseases

Applied Therapeutics remains firm in its commitment to advancing research and development across its portfolio. The ongoing focus on govorestat is coupled with a robust safety profile seen in patients treated for over four years across various indications.

Corporate Developments

Leadership Transition

In a recent corporate update, it was announced that John Johnson would be stepping down from his role as Executive Chairman of the Board. Importantly, his decision did not stem from any disagreements concerning company strategies or operations. This leadership transition indicates a shift towards strengthening company governance as it moves forward in clinical trials and regulatory discussions.

Financial Results Overview

Performance Metrics

As of September 30, 2025, Applied Therapeutics reported cash and cash equivalents of $11.9 million, a significant decrease from $79.4 million at the end of 2024. The overall cash position reflects focused spending on clinical trials.

Research and development expenses were reported at $9.6 million, down from $14.8 million during the same period last year, indicating a strategic realignment in operational expenses. Administrative expenses also saw a decline to $8.2 million from $15.0 million, further highlighting the company's focus on cost management.

Net Loss Insights

The company reported a net loss of $19.0 million for the third quarter, translating to $0.13 per share, a notable improvement compared to a larger net loss of $68.6 million in the corresponding period of the previous year. This recovery reflects operational efficiencies and strategic prioritization of projects.

About Applied Therapeutics

Applied Therapeutics is known for its dedication to developing innovative treatments targeting validated biomarkers in rare diseases. The lead candidate, govorestat, represents a new approach in addressing metabolic disorders affecting the central nervous system.

The company encourages interested parties to learn more about its pioneering work by visiting their official website and connecting with them on social media.

Frequently Asked Questions

What are the latest updates on Applied Therapeutics' regulatory strategies?

Applied Therapeutics has engaged in discussions with the FDA regarding its lead candidate, govorestat, focusing on treatments for rare diseases.

How did the company perform financially in the third quarter?

The company reported a net loss of $19.0 million, showing an improvement over previous years, reflecting operational efficiencies.

What significant clinical findings were reported?

Recent discussions noted a substantial decrease in sorbitol levels in a patient receiving govorestat for the treatment of PMM2-CDG.

Is the company undergoing any leadership changes?

Yes, John Johnson has announced his resignation as Executive Chairman, which aims to facilitate a constructive governance transition.

What is govorestat's potential impact?

Govorestat holds promise for patients with rare metabolic diseases and has demonstrated a robust safety profile in clinical trials.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 58

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 58

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 162

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 144

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 114

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Palantir: A Promising Investment Opportunity

Updated Category News Views 200

The Rise of Palantir Technologies Palantir Technologies (NYSE: PLTR) has emerged as a notable force in the stock market, especially in the field of artificial intelligence (AI). Known for its complex data analytics platforms, Palantir was founded after the September 11 attacks to offer essential software solutions to federal intelligence agencies, assisting them in...

Continue Reading
Castellum, Inc. Achieves Record Revenue and Debt Reduction

Updated Category News Views 176

Castellum, Inc. Reports Impressive Q2 Financial Results Castellum, Inc. (NYSE-American: CTM), a prominent player in cybersecurity, electronic warfare, and software services directed towards the federal government, recently unveiled its financial results for the second quarter of 2025. The results showcase a record revenue performance, enhanced operational efficiencies,...

Continue Reading
Revolutionary Ultra H2 Wheelset by Superteam Wheels Debuts

Updated Category News Views 441

Introducing the Ultra H2 Wheelset Superteam Wheels, a notable name in the cycling industry, has taken a major step forward with the launch of their Ultra H2 Special Edition Wheelset. This new product is set to redefine the standards of performance wheels, appealing to cycling enthusiasts who seek the perfect blend of speed, reliability, and design. Advanced Technology at...

Continue Reading
Family Care Center's IOP Secures Three-Year CARF Accreditation

Updated Category News Views 200

Family Care Center Achieves Notable CARF Accreditation Family Care Center, a prominent national provider in behavioral health care, has recently announced a significant milestone: its intensive outpatient program (IOP) has earned a coveted three-year accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF). This accomplishment not only...

Continue Reading
Entergy Boosts Quarterly Dividend to Support Shareholders

Updated Category News Views 169

Entergy Announces Dividend Increase for Shareholders Entergy's board of directors has recently made a significant decision to enhance shareholder value. They declared a quarterly dividend payment of $0.64 per share, marking a notable increase of $0.04 per share. This increment reflects the company's ongoing commitment to rewarding its investors. Dividend Payment Schedule...

Continue Reading